Valuation: BriaCell Therapeutics Corp.

Market Cap 28.46M 24.88M 22.86M 21.31M 40.42M 2.71B 41.03M 274M 107M 1.33B 107M 105M 4.59B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 10.59M 9.26M 8.51M 7.93M 15.04M 1.01B 15.27M 102M 39.71M 496M 39.75M 38.9M 1.71B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day-1.94%
1 week+4.60%
Current month-1.94%
1 month-0.66%
3 months-24.54%
6 months-57.75%
Current year-53.57%
1 week 4.36
Extreme 4.36
5
1 month 3.68
Extreme 3.68
5
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
40.6
3 years 3.68
Extreme 3.68
1,543.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 2016-10-31
Director of Finance/CFO 54 2016-01-31
Chief Tech/Sci/R&D Officer 65 2022-02-15
Director TitleAgeSince
Director/Board Member 70 2016-10-31
Chairman 41 2019-04-23
Director/Board Member 73 2019-03-06
Date Insider Type Main position Quantity % Market Cap.
02-18Option

Chief Technology Officer

30,000 0.4830%
02-18Option

Chief Financial Officer

30,000 0.4830%
02-18Option

Chief Technology Officer

30,000 0.4830%
Change 5-day change 1-year change 3-year change Capi.($)
-1.94%+4.60%-88.65%-99.65% 28.46M
+0.68%+6.27%+77.60%+133.76% 58.73B
+2.32%+5.89%+76.81%+99.20% 53.92B
-10.61%+8.38%-9.90%-9.62% 24.67B
-0.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.47%+46.43%+0.03% 18.8B
-0.29%+9.78%+44.62%-27.94% 17.61B
0.00%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+20.94%+51.67% - 13.9B
Average +2.39%+7.52%+40.94%+119.21% 24.21B
Weighted average by Cap. +2.44%+5.53%+59.08%+137.28%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.19M -3.85M -3.59M -6.81M -456M -6.91M -46.21M -17.97M -224M -17.99M -17.6M -773M -26.31M -23M -21.14M -19.7M -37.37M -2.51B -37.94M -254M -98.65M -1.23B -98.76M -96.64M -4.24B
Net Debt -862K -754K -693K -646K -1.22M -82.08M -1.24M -8.31M -3.23M -40.35M -3.24M -3.17M -139M -17.87M -15.62M -14.35M -13.38M -25.38M -1.7B -25.76M -172M -66.99M -836M -67.06M -65.62M -2.88B
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
26-07-03 $4.550 -1.94% 1,800
26-07-02 $4.640 0.00% 5,467
26-06-30 $4.640 +4.98% 2,118
26-06-29 $4.420 +1.61% 5,970
26-06-26 $4.350 +3.82% 5,900

Quarterly revenue - Rate of surprise